



Press Release

TxCell announces its financial calendar for 2016

Valbonne, France, January 6, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, today announces its financial calendar for 2016.

Tuesday, February 2, 2016:	Publication of full year 2015 revenues (after market)
Tuesday, April 5, 2016:	Publication of 2015 annual results (after market)
Tuesday, May 10, 2016:	Publication of Q1 2016 revenues (after market)
Wednesday, June 1, 2016 :	Annual shareholder's meeting
Wednesday, July 27, 2016:	Publication of Q2 2016 revenues (after market)
Tuesday, September 27, 2016:	Publication of H1 2016 results (after market)
Tuesday, November 8, 2016:	Publication of Q3 2016 revenues (after market)

In addition to these updates, investors can consult the Company's website (www.txcell.com) where information is regularly updated. All corporate and financial information on the Company is available on the Company's website in the Finance section.

This schedule is indicative and subject to change.

About TxCell: www.txcell.com

TxCell is a publicly listed biopharmaceutical company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell's lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 60 employees.

Contacts:

TxCell
Raphaël Flipo
CFO
Tél: +33 4 97 21 83 00
contact@txcell.com

NewCap
Financial Communication
Julien Perez / Pierre Laurent
Tél: +33 1 44 71 94 94
txcell@newcap.eu



Disclaimer:

This press release contains certain forward-looking statements concerning TxCell and its business. Such forward-looking statements are based on assumptions that TxCell considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of TxCell registered by the French Financial Markets Authority (*Autorité des marchés financiers*) on June 11, 2015 under number R. 15-049 and in the half year financial report of TxCell as of June 30, 2015 (a copy of which is available on www.txcell.com) and to the development of economic conditions, financial markets and the markets in which TxCell operates. The forward-looking statements contained in this press release are also subject to risks not yet known to TxCell or not currently considered material by TxCell. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of TxCell to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, TxCell shares in any country.